DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $12.3333.

A number of equities analysts recently commented on the stock. Wall Street Zen downgraded shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. TD Cowen started coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Cantor Fitzgerald began coverage on DiaMedica Therapeutics in a report on Friday, November 14th. They issued an “overweight” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st.

Insiders Place Their Bets

In related news, major shareholder Jan Stahlberg acquired 73,099 shares of the firm’s stock in a transaction on Tuesday, November 25th. The stock was bought at an average price of $8.57 per share, for a total transaction of $626,458.43. Following the completion of the purchase, the insider directly owned 8,825,742 shares of the company’s stock, valued at approximately $75,636,608.94. The trade was a 0.84% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders have acquired 1,061,277 shares of company stock valued at $7,632,627 over the last three months. 7.30% of the stock is owned by insiders.

Institutional Trading of DiaMedica Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cooperman Leon G boosted its position in shares of DiaMedica Therapeutics by 98.2% in the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the period. Millennium Management LLC acquired a new stake in shares of DiaMedica Therapeutics in the third quarter valued at approximately $8,157,000. Geode Capital Management LLC grew its position in shares of DiaMedica Therapeutics by 99.6% during the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock worth $2,458,000 after acquiring an additional 314,407 shares during the last quarter. Paragon Associates & Paragon Associates II Joint Venture increased its holdings in shares of DiaMedica Therapeutics by 34.6% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after acquiring an additional 225,000 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of DiaMedica Therapeutics by 46,879.1% in the 1st quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after acquiring an additional 154,701 shares during the period. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $8.53 on Friday. The business has a 50-day simple moving average of $8.36 and a 200-day simple moving average of $7.18. The company has a market cap of $444.24 million, a PE ratio of -12.01 and a beta of 1.11. DiaMedica Therapeutics has a one year low of $3.19 and a one year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, sell-side analysts predict that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.